دورية أكاديمية
أعرض في EDS

Travel-time barriers to specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia.

التفاصيل البيبلوغرافية
العنوان: Travel-time barriers to specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia.
المؤلفون: Parsons HM; Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA., Garcia A; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA., Zhang A; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA., Miller K; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA., Van Riper D; Minnesota Population Center, University of Minnesota, Minneapolis, MN, USA., Knowles K; Minnesota Population Center, University of Minnesota, Minneapolis, MN, USA., Keegan TH; Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis School of Medicine, Sacramento, CA, USA.
المصدر: JNCI cancer spectrum [JNCI Cancer Spectr] 2024 Jul 01; Vol. 8 (4).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Oxford University Press, [2017]-
مواضيع طبية MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy , Health Services Accessibility*/statistics & numerical data , Travel*/statistics & numerical data , Cancer Care Facilities*/statistics & numerical data, Humans ; Adolescent ; Male ; Female ; Young Adult ; Adult ; United States ; Time Factors ; Logistic Models ; Registries
مستخلص: Background: Prior studies demonstrate that 20%-50% of adolescents and young adults (age 15-39 years) with acute lymphoblastic leukemia (ALL) receive care at specialty cancer centers, yet a survival benefit has been observed for patients at these sites. Our objective was to identify patients at risk of severe geographic barriers to specialty cancer center-level care.
Methods: We used data from the North American Association of Central Cancer Registries Cancer in North America database to identify adolescent and young adult ALL patients diagnosed between 2004 and 2016 across 43 US states. We calculated driving distance and travel time from counties where participants lived to the closest specialty cancer center sites. We then used multivariable logistic regression models to examine the relationship between sociodemographic characteristics of counties where adolescent and young adult ALL patients resided and the need to travel more than 1 hour to obtain care at a specialty cancer center.
Results: Among 11 813 adolescent and young adult ALL patients, 43.4% were aged 25-39 years, 65.5% were male, 32.9% were Hispanic, and 28.7% had public insurance. We found 23.6% of adolescent and young adult ALL patients from 60.8% of included US counties would be required to travel more than 1 hour one way to access a specialty cancer center. Multivariable models demonstrate that patients living in counties that are nonmetropolitan, with lower levels of educational attainment, with higher income inequality, with lower internet access, located in primary care physician shortage areas, and with fewer hospitals providing chemotherapy services are more likely to travel more than 1 hour to access a specialty cancer center.
Conclusions: Substantial travel-related barriers exist to accessing care at specialty cancer centers across the United States, particularly for patients living in areas with greater concentrations of historically marginalized communities.
(© The Author(s) 2024. Published by Oxford University Press.)
References: Br J Haematol. 2016 Apr;173(2):292-302. (PMID: 26847024)
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):154-160. (PMID: 30504304)
Int J Gynecol Cancer. 2014 Sep;24(7):1232-40. (PMID: 25153678)
J Adolesc Young Adult Oncol. 2019 Jun;8(3):254-261. (PMID: 30657424)
JCO Oncol Pract. 2023 Dec;19(12):1190-1198. (PMID: 37890123)
Blood Adv. 2018 Apr 24;2(8):895-903. (PMID: 29669756)
J Rural Health. 2012 Jan;28(1):54-62. (PMID: 22236315)
Leukemia. 2018 Mar;32(3):606-615. (PMID: 28819280)
J Clin Oncol. 2015 Sep 20;33(27):2938-48. (PMID: 26304874)
J Oncol Pract. 2019 Apr;15(4):e316-e327. (PMID: 30849003)
Oncologist. 2015 Dec;20(12):1378-85. (PMID: 26512045)
Pediatr Blood Cancer. 2018 Jun;65(6):e26989. (PMID: 29418064)
J Oncol Pract. 2019 Mar;15(3):e219-e229. (PMID: 30702962)
Pediatr Blood Cancer. 2022 May;69(5):e29546. (PMID: 35107854)
Womens Health Rep (New Rochelle). 2021 Jan 11;2(1):1-10. (PMID: 33786524)
Oncologist. 2014 Mar;19(3):283-90. (PMID: 24569946)
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320. (PMID: 28209594)
Am J Manag Care. 2021 Aug;27(6 Spec No.):SP241-SP244. (PMID: 34407362)
Cancer. 2017 Jan 1;123(1):122-130. (PMID: 27622953)
Soc Theory Health. 2018 Aug;16(3):224-240. (PMID: 31007612)
Leuk Lymphoma. 2018 Oct;59(10):2482-2484. (PMID: 29424251)
Soc Sci Med. 2001 Jun;52(12):1777-91. (PMID: 11352405)
J Clin Oncol. 2019 Aug 1;37(22):1935-1945. (PMID: 31184952)
Cancer. 2008 Feb 15;112(4):909-18. (PMID: 18189295)
J Natl Cancer Inst. 2001 Sep 5;93(17):1344-6. (PMID: 11535710)
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e477-e484. (PMID: 35125333)
J Rural Health. 2009 Fall;25(4):366-71. (PMID: 19780916)
Cancer. 2018 May 1;124(9):1938-1945. (PMID: 29451695)
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):17-23. (PMID: 31808881)
Blood Adv. 2020 Apr 14;4(7):1538. (PMID: 32289165)
Hematol Oncol Clin North Am. 2014 Dec;28(6):1201-13. (PMID: 25459188)
J Clin Oncol. 2014 Mar 20;32(9):942-8. (PMID: 24516014)
معلومات مُعتمدة: P30 CA077598 United States CA NCI NIH HHS; National Institutes of Health UC Davis Comprehensive Cancer Center; #PHP9004-21 Leukemia and Lymphoma Society; National Institutes of Health Masonic Cancer Center
تواريخ الأحداث: Date Created: 20240606 Date Completed: 20240708 Latest Revision: 20240710
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC11229987
DOI: 10.1093/jncics/pkae046
PMID: 38845074
قاعدة البيانات: MEDLINE
الوصف
تدمد:2515-5091
DOI:10.1093/jncics/pkae046